CN113817666A - 一种全悬浮培养bhk-21细胞的cd培养基及其摇瓶培养工艺 - Google Patents
一种全悬浮培养bhk-21细胞的cd培养基及其摇瓶培养工艺 Download PDFInfo
- Publication number
- CN113817666A CN113817666A CN202111190990.6A CN202111190990A CN113817666A CN 113817666 A CN113817666 A CN 113817666A CN 202111190990 A CN202111190990 A CN 202111190990A CN 113817666 A CN113817666 A CN 113817666A
- Authority
- CN
- China
- Prior art keywords
- culture
- cells
- group
- bhk
- components
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000001963 growth medium Substances 0.000 title claims abstract description 33
- 238000000034 method Methods 0.000 title claims abstract description 27
- 238000004114 suspension culture Methods 0.000 title claims abstract description 22
- 238000012807 shake-flask culturing Methods 0.000 title claims abstract description 14
- 150000002632 lipids Chemical group 0.000 claims abstract description 18
- 239000011573 trace mineral Substances 0.000 claims abstract description 18
- 235000013619 trace mineral Nutrition 0.000 claims abstract description 18
- 229940088594 vitamin Drugs 0.000 claims abstract description 18
- 229930003231 vitamin Natural products 0.000 claims abstract description 18
- 235000013343 vitamin Nutrition 0.000 claims abstract description 18
- 239000011782 vitamin Substances 0.000 claims abstract description 18
- 150000003722 vitamin derivatives Chemical group 0.000 claims abstract description 18
- 239000000872 buffer Chemical group 0.000 claims abstract description 15
- 150000001720 carbohydrates Chemical group 0.000 claims abstract description 15
- 150000003839 salts Chemical class 0.000 claims abstract description 14
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 11
- 238000005303 weighing Methods 0.000 claims abstract description 10
- 238000001914 filtration Methods 0.000 claims abstract description 5
- 238000002156 mixing Methods 0.000 claims abstract description 4
- 239000002609 medium Substances 0.000 claims description 21
- 238000011081 inoculation Methods 0.000 claims description 19
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 15
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- 230000012010 growth Effects 0.000 claims description 12
- 235000014633 carbohydrates Nutrition 0.000 claims description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 7
- 238000004113 cell culture Methods 0.000 claims description 7
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 7
- 235000020778 linoleic acid Nutrition 0.000 claims description 7
- CMZUMMUJMWNLFH-UHFFFAOYSA-N sodium metavanadate Chemical compound [Na+].[O-][V](=O)=O CMZUMMUJMWNLFH-UHFFFAOYSA-N 0.000 claims description 6
- 230000010261 cell growth Effects 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000001569 carbon dioxide Substances 0.000 claims description 4
- 229910017053 inorganic salt Inorganic materials 0.000 claims description 4
- 230000003204 osmotic effect Effects 0.000 claims description 4
- 238000011084 recovery Methods 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 238000012360 testing method Methods 0.000 claims description 4
- 229910021642 ultra pure water Inorganic materials 0.000 claims description 4
- 239000012498 ultrapure water Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 239000000654 additive Chemical group 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 3
- 239000000413 hydrolysate Chemical group 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 5
- 239000012528 membrane Substances 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 50
- 239000000306 component Substances 0.000 description 39
- 210000002966 serum Anatomy 0.000 description 8
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 6
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 6
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 6
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 6
- 239000013065 commercial product Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- YBMRDBCBODYGJE-UHFFFAOYSA-N germanium dioxide Chemical compound O=[Ge]=O YBMRDBCBODYGJE-UHFFFAOYSA-N 0.000 description 4
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 4
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 3
- 235000019743 Choline chloride Nutrition 0.000 description 3
- 241000699800 Cricetinae Species 0.000 description 3
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 3
- 229960002079 calcium pantothenate Drugs 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 229960003178 choline chloride Drugs 0.000 description 3
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 3
- 229960002104 cyanocobalamin Drugs 0.000 description 3
- 235000000639 cyanocobalamin Nutrition 0.000 description 3
- 239000011666 cyanocobalamin Substances 0.000 description 3
- 229960000304 folic acid Drugs 0.000 description 3
- 235000019152 folic acid Nutrition 0.000 description 3
- 239000011724 folic acid Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 229960000367 inositol Drugs 0.000 description 3
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 3
- 210000003292 kidney cell Anatomy 0.000 description 3
- 229960003966 nicotinamide Drugs 0.000 description 3
- 235000005152 nicotinamide Nutrition 0.000 description 3
- 239000011570 nicotinamide Substances 0.000 description 3
- 235000008160 pyridoxine Nutrition 0.000 description 3
- 239000011677 pyridoxine Substances 0.000 description 3
- 229960002477 riboflavin Drugs 0.000 description 3
- 235000019192 riboflavin Nutrition 0.000 description 3
- 239000002151 riboflavin Substances 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 3
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 3
- 229960000344 thiamine hydrochloride Drugs 0.000 description 3
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 3
- 239000011747 thiamine hydrochloride Substances 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 229940011671 vitamin b6 Drugs 0.000 description 3
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 2
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 2
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 2
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 2
- 239000004115 Sodium Silicate Substances 0.000 description 2
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 235000021120 animal protein Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- UXVMQQNJUSDDNG-HDMMMHCHSA-L calcium-45(2+);dichloride Chemical compound [Cl-].[Cl-].[45Ca+2] UXVMQQNJUSDDNG-HDMMMHCHSA-L 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 229910000365 copper sulfate Inorganic materials 0.000 description 2
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000011790 ferrous sulphate Substances 0.000 description 2
- 235000003891 ferrous sulphate Nutrition 0.000 description 2
- 229940119177 germanium dioxide Drugs 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 2
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 2
- 235000019136 lipoic acid Nutrition 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000011565 manganese chloride Substances 0.000 description 2
- 235000002867 manganese chloride Nutrition 0.000 description 2
- 229940099607 manganese chloride Drugs 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000004017 serum-free culture medium Substances 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000011684 sodium molybdate Substances 0.000 description 2
- 235000015393 sodium molybdate Nutrition 0.000 description 2
- TVXXNOYZHKPKGW-UHFFFAOYSA-N sodium molybdate (anhydrous) Chemical compound [Na+].[Na+].[O-][Mo]([O-])(=O)=O TVXXNOYZHKPKGW-UHFFFAOYSA-N 0.000 description 2
- 239000011781 sodium selenite Substances 0.000 description 2
- 235000015921 sodium selenite Nutrition 0.000 description 2
- 229960001471 sodium selenite Drugs 0.000 description 2
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 2
- 229910052911 sodium silicate Inorganic materials 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000001119 stannous chloride Substances 0.000 description 2
- 235000011150 stannous chloride Nutrition 0.000 description 2
- 229960002663 thioctic acid Drugs 0.000 description 2
- 239000005723 virus inoculator Substances 0.000 description 2
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 2
- 229910000368 zinc sulfate Inorganic materials 0.000 description 2
- 229960001763 zinc sulfate Drugs 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241000711404 Avian avulavirus 1 Species 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 201000005807 Japanese encephalitis Diseases 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 241000907316 Zika virus Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229960003127 rabies vaccine Drugs 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
- C12N5/0686—Kidney cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/02—Atmosphere, e.g. low oxygen conditions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
- C12N2500/14—Calcium; Ca chelators; Calcitonin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
- C12N2500/16—Magnesium; Mg chelators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/22—Zinc; Zn chelators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/34—Sugars
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/36—Lipids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明公开了一种全悬浮培养BHK‑21细胞的CD培养基及其摇瓶培养工艺,包括下列步骤:1)按配比称量培养基中各组成分;2)将称量好的氨基酸组;维生素组;无机盐与微量元素组;脂类、糖类与缓冲剂组溶解;3)将溶解好的各组成分混合,用0.2μm的滤膜过滤,获得悬浮培养BHK‑21细胞的CD培养基;本发明所述悬浮培养BHK‑21细胞的CD培养基具有成本低廉、安全性高、污染风险小、批间差小且稳定好的特点,并且具有制作快速、高效、低成本的优异效果。
Description
技术领域
本发明涉及细胞培养生物技术领域,尤其涉及一种全悬浮培养BHK-21细胞的CD培养基及其摇瓶培养工艺。
背景技术
BHK-21是幼地鼠肾脏细胞,可用于多种疫苗的大规模生产,如口蹄疫疫苗和狂犬疫苗,同时日本乙型脑炎病毒、寨卡病毒以及特定的流感病毒株如A/WSN/33[H1N1](WSN)等也可在该细胞中增殖。因此该细胞在兽用疫苗中占据主要位置,市场份额巨大,前景广阔。
目前,国内生物疫苗生产企业培养BHK-21细胞生产口蹄疫疫苗时,会遇到细胞密度低,病毒产率低,生产成本高,培养和接毒过程中需要更换培养基等问题。
传统BHK-21细胞培养基中往往需要添加血清,血清作为细胞生长和维持的重要物质,在细胞培养过程中发挥重要作用的同时,也带来许多问题和弊端,例如血清的成分复杂,不能完全去除;血清批次间差异大,保质期短,不利于大规模连续生产;血清还可能携带动物源性的其他微生物,如病毒、支原体、衣原体等,影响生产的安全性;血清中还含有大量动物蛋白,影响下游的分离和纯化,增加人力和成本。虽然目前市面上已经开始有BHK-21细胞培养基生产出来,但是大多培养基还是添加有动物蛋白胰岛素、转铁蛋白和白蛋白等影响批间效果的物质,同样不利于大规模低成本化生产。无血清无蛋白化学成分限定的培养基是该工艺的实现产业化的技术难点,采用成分明确、细胞能高密度生长,而且还有较高的病毒表达量,将起到事半功倍的效果。现有技术中,国外细胞无血清培养基配方保密且价格高,同时市场上已有培养基(国内、国外)成分均不明确。
综合以上,目前国内亟需一种支持BHK-21细胞快速高密生长的、价格廉价的、化学成分限定的CD培养基及开发过程中涉及的培养工艺。
发明内容
本发明的提供一种全悬浮培养BHK-21细胞的CD培养基及其摇瓶培养工艺。
本发明的方案是:
一种全悬浮培养BHK-21细胞的CD培养基,包括下列原料组成,氨基酸组;维生素组;无机盐与微量元素组;脂类、糖类与缓冲剂组,其中,
氨基酸组
维生素组
无机盐与微量元素组
脂类、水解物与添加物组
本发明还公开了一种所述的全悬浮培养BHK-21细胞的CD培养基在无血清动物细胞培养中摇瓶培养工艺。
作为优选的技术方案,所述血清动物细胞为悬浮的幼仓鼠肾脏细胞。
作为优选的技术方案,所述全悬浮培养BHK-21细胞的CD培养基在悬浮的幼仓鼠肾脏细胞培养中使用多宁生物的125毫升的摇瓶培养。
本发明还公开了一种全悬浮培养BHK-21细胞的CD培养基在悬浮BHK-21细胞培养中使用125毫升摇瓶培养的培养工艺。
该BHK-21细胞在CD培养基中的摇瓶培养过程中的细胞接种密度、细胞传代代次、培养的二氧化碳浓度、培养温度对BHK-21细胞生长影响做了监测和统计,优选出适合的摇瓶培养工艺;
作为优选的技术方案,包括低密和高密两种接种密度接种,其中低密的接种密度为3E5,高密的接种密度为10E5;选择经过不同代次的BHK21细胞,F10和F40,F10为复苏后经过10次传代的BHK21细胞,F40为复苏后经过40次传代的BHK21细胞;
作为优选的技术方案,包括5%CO2和8%CO2两种不同含量的二氧化碳浓度进行摇瓶培养测试BHK21细胞生长;
作为优选的技术方案,包括32.5℃和36.5℃两种不同温度进行摇瓶培养测试BHK21细胞生长。
由于采用了上述技术方案,获得了全悬浮培养BHK-21细胞的CD培养基及其配套的摇瓶培养工艺。
本发明的有益效果在于:
本发明所述悬浮培养BHK-21细胞的CD培养基,具有成本低廉、安全性高、污染风险小、批间差小且稳定好的特点,并且具有制备快速、高效、低成本的效果;该培养基能适用于多种不同无血清培养基培养的BHK-21细胞株,培养效果好,支持1E5~1E6区间的各种接种密度,1E6接种48小时内细胞密度超过1E7,细胞活率始终维持在99%以上,可同时做为口蹄疫病毒、新城疫病毒的直接接毒培养基,整个培养过程中无需更换培养基,培养基成分明确,有利于下游的分离和纯化。能够支持BHK21细胞生长、稳定传代和接毒的一体化培养基,完全满足了高密悬浮培养规模化工业生产的需求。
本发明还阐明了针对此款CD培养基还具有对应的摇瓶生产工艺,就细胞的接种密度、细胞的不同培养代次、培养时的二氧化碳浓度、培养温度进行了对比,确定了最适合此培养基的最适摇瓶培养工艺。
附图说明
为了更清楚地说明本发明实施例或现有技术中的技术方案,下面将对实施例中所需要使用的附图作简单地介绍,显而易见地,下面描述中的附图仅仅是本发明的一些实施例,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据这些附图获得其他的附图。
图1是悬浮的BHK21细胞在不同的市售培养基和本发明中的CD培养基中的生长对比图。
图2是BHK21细胞在CD培养基中不同密度接种的生长情况图,其中虚线为低密(3E5)接种的生长曲线和细胞活率,实线为高密(1E6)接种的生长曲线和细胞活率;浅色为CD培养基,深色为市售产品3。
图3是体外培养第10代(F10)和第40代(F40)在CD培养基中的生长曲线图。
图4是36.5℃时体外培养第10代(F10)的BHK21细胞在CD培养基中分别在5%CO2和8%CO2培养下的生长曲线图。
图5是8%CO2时体外培养第10代(F10)的BHK21细胞在CD培养基中分别在32.5℃和36.5℃培养下的生长曲线图。
具体实施方式
为了弥补以上不足,本发明提供了一种全悬浮培养BHK-21细胞的CD培养基及其摇瓶培养工艺,以解决上述背景技术中的问题。
一种悬浮培养BHK-21细胞的CD培养基,包括下列原料组成,氨基酸组;维生素组;无机盐与微量元素组;脂类、糖类与缓冲剂组,其中,
氨基酸组
维生素组
无机盐与微量元素组
脂类、水解物与添加物组
为了更好的阐述该CD培养基及其摇瓶培养工艺,以下分不同的实施例说明情况。
实施例1
各物料浓度如下:
氨基酸
维生素
成份 | 含量范围mg/L | 成份 | 含量范围mg/L |
α-硫辛酸 | 2 | 烟酰胺 | 3 |
氰钴胺素 | 1.1 | 硫胺盐酸盐 | 3.2 |
生物素 | 2.2 | 核黄素 | 0.35 |
叶酸 | 4 | 对氨基苯甲酸 | 1.2 |
维生素C | 18 | 吡哆醇 | 4 |
泛酸钙 | 3 | 氯化胆碱 | 66 |
肌醇 | 85 |
无机盐和微量元素
脂类,糖类,缓冲剂
成份 | 含量范围mg/L | 成份 | 含量范围mg/L |
亚油酸 | 0.08 | P188 | 1800 |
丙酮酸钠 | 160 | HEPES | 1500 |
葡萄糖 | 6000 |
1)按配比称量培养基中各组成分;
2)将称量好的氨基酸组;维生素组;无机盐与微量元素组;脂类、糖类与缓冲剂组溶解;其中所述维生素组的成分中α-硫辛酸、叶酸、核黄素与生物素使用0.4mol/L的NaOH溶解;所述无机盐与微量元素组的成分中偏钒酸钠使用6mol/L HCl溶解;脂类、糖类与缓冲剂组的成分中亚油酸通过无水乙醇溶解;其他各组的成分使用超纯水溶解;
3)将溶解好的各组成分混合,调节pH在7.0~7.4;加水定容,随后利用氯化钠调节渗透压在280~350mOsm/kg;用0.22μm的滤膜过滤,获得悬浮培养BHK-21细胞的CD培养基,使用新复苏的F3-F10的BHK21细胞,以3E5的接种密度,30ml的体系培养于上海多宁的125ml摇瓶中,再放入上海多宁的DNSI0101摇床中培养,摇床设定参数为:8%CO2、36.5℃和110rmp,整个培养过程无需补糖补料,只在接种后的第三天开始每天取样记录活细胞密度即可。
如图1所示,此CD培养基与市售产品1(苏州天信和BHK21培养基)、市售产品2(甘肃建顺BHK21培养基)和市售产品3(源培生物BHK21培养基)在细胞的batch生长上对比发现,CD培养基均表现出显著的优势。
实施例2
氨基酸
维生素
成份 | 含量范围mg/L | 成份 | 含量范围mg/L |
α-硫辛酸 | 2 | 烟酰胺 | 3 |
氰钴胺素 | 1.1 | 硫胺盐酸盐 | 3.2 |
生物素 | 2.2 | 核黄素 | 0.35 |
叶酸 | 4 | 对氨基苯甲酸 | 1.2 |
维生素C | 18.5 | 吡哆醇 | 4 |
泛酸钙 | 3 | 氯化胆碱 | 68 |
肌醇 | 85 |
无机盐和微量元素
成份 | 含量范围mg/L | 成份 | 含量范围mg/L |
氯化钾 | 720 | 硫酸亚铁 | 0.55 |
碳酸氢钠 | 2100 | 硅酸钠 | 0.45 |
氯化钙 | 55 | 氯化锰 | 0.01 |
磷酸氢二钠 | 700 | 偏钒酸钠 | 0.0035 |
氯化亚锡 | 0.05 | 钼酸钠 | 0.005 |
硫酸锌 | 2.7 | 亚硒酸钠 | 0.004 |
硫酸镁 | 75 | 硫酸铜 | 0.1 |
氯化锂 | 0.05 | 二氧化锗 | 0.01 |
脂类,糖类,缓冲剂
成份 | 含量范围mg/L | 成份 | 含量范围mg/L |
亚油酸 | 0.08 | P188 | 1800 |
丙酮酸钠 | 163 | HEPES | 1480 |
葡萄糖 | 6000 |
1)按配比称量培养基中各组成分;
2)将称量好的氨基酸组;维生素组;无机盐与微量元素组;脂类、糖类与缓冲剂组溶解;其中所述维生素组的成分中α-硫辛酸、叶酸、核黄素与生物素使用0.4mol/L的NaOH溶解;所述无机盐与微量元素组的成分中偏钒酸钠使用6mol/L HCl溶解;脂类、糖类与缓冲剂组的成分中亚油酸通过无水乙醇溶解;其他各组的成分使用超纯水溶解;
3)将溶解好的各组成分混合,调节pH在7.0~7.4;加水定容,随后利用氯化钠调节渗透压在280~350mOsm/kg;用0.22μm的滤膜过滤,获得悬浮培养BHK-21细胞的CD培养基,然后使用新复苏的F3-F10的BHK21细胞,在3E5和10E5两种接种密度下,30ml的体系培养于上海多宁的125ml摇瓶中,再放入上海多宁的DNSI0101摇床中培养,摇床设定参数为:8%CO2、36.5℃和110rmp,整个培养过程无需补糖补料,只在接种后的第三天开始每天取样记录活细胞密度即可。
如图2所示,此CD培养基在低密和高密接种条件下均能很好适应细胞,最高活细胞密度一致,值得注意也与我们的假设一致,高密接种的细胞生长的最大活细胞密度所需的时间大大缩短。CD培养基对比市售产品3(源培生物BHK21培养基),无论低密接种还是高密接种,市售产品均不及CD培养基,由此显示CD培养基具有非常稳定的特征。
实施例3
氨基酸
维生素
成份 | 含量范围mg/L | 成份 | 含量范围mg/L |
α-硫辛酸 | 2 | 烟酰胺 | 3 |
氰钴胺素 | 1.1 | 硫胺盐酸盐 | 3.2 |
生物素 | 2.2 | 核黄素 | 0.35 |
叶酸 | 4 | 对氨基苯甲酸 | 1.2 |
维生素C | 18.5 | 吡哆醇 | 4 |
泛酸钙 | 3 | 氯化胆碱 | 66 |
肌醇 | 85 |
无机盐和微量元素
成份 | 含量范围mg/L | 成份 | 含量范围mg/L |
氯化钾 | 720 | 硫酸亚铁 | 0.52 |
碳酸氢钠 | 2100 | 硅酸钠 | 0.45 |
氯化钙 | 55 | 氯化锰 | 0.01 |
磷酸氢二钠 | 700 | 偏钒酸钠 | 0.0035 |
氯化亚锡 | 0.05 | 钼酸钠 | 0.005 |
硫酸锌 | 2.7 | 亚硒酸钠 | 0.004 |
硫酸镁 | 75 | 硫酸铜 | 0.1 |
氯化锂 | 0.05 | 二氧化锗 | 0.01 |
脂类,糖类,缓冲剂
成份 | 含量范围mg/L | 成份 | 含量范围mg/L |
亚油酸 | 0.08 | P188 | 1800 |
丙酮酸钠 | 160 | HEPES | 1500 |
葡萄糖 | 6000 |
1)按配比称量培养基中各组成分;
2)将称量好的氨基酸组;维生素组;无机盐与微量元素组;脂类、糖类与缓冲剂组溶解;其中所述维生素组的成分中α-硫辛酸、叶酸、核黄素与生物素使用0.4mol/L的NaOH溶解;所述无机盐与微量元素组的成分中偏钒酸钠使用6mol/L HCl溶解;脂类、糖类与缓冲剂组的成分中亚油酸通过无水乙醇溶解;其他各组的成分使用超纯水溶解;
3)将溶解好的各组成分混合,调节pH在7.0~7.4;加水定容,随后利用氯化钠调节渗透压在280~350mOsm/kg;用0.22μm的滤膜过滤,获得悬浮培养BHK-21细胞的CD培养基,使用F10和F40代BHK21细胞在30ml的体系培养于上海多宁的125ml摇瓶中,再放入上海多宁的DNSI0101摇床中培养,摇床设定如下:
条件1:8%CO2、36.5℃和110rmp
条件2:5%CO2、36.5℃和110rmp
条件3:8%CO2、32.5℃和110rmp
上述条件下进行batch培养,整个培养过程无需补糖补料,只在接种后的第三天开始每天取样记录活细胞密度即可。
如图3-图5所示,此CD培养基最适合的摇瓶培养工艺是条件1:8%CO2、36.5℃和110rmp。
以上结果显示和描述了本发明的基本原理、主要特征及本发明的优点。本行业的技术人员应该了解,本发明不受上述实施例的限制,上述实施例和说明书中描述的只是说明本发明的原理,在不脱离本发明精神和范围的前提下,本发明还会有各种变化和改进,这些变化和改进都落入要求保护的本发明范围内。本发明要求保护范围由所附的权利要求书及其等效物界定。
Claims (6)
2.一种制备如权利要求1中所述的全悬浮培养BHK-21细胞的CD培养基的方法,其特征在于,包括下列步骤:
1)按配比称量培养基中各组成分;
2)将称量好的氨基酸组;维生素组;无机盐与微量元素组;脂类、糖类与缓冲剂组溶解;其中所述维生素组的成分中α-硫辛酸、叶酸、核黄素与生物素使用0.4mol/L的NaOH溶解;所述无机盐与微量元素组的成分中偏钒酸钠使用6mol/L HCl溶解;脂类、糖类与缓冲剂组的成分中亚油酸通过无水乙醇溶解;其他各组的成分使用超纯水溶解;
3)将溶解好的各组成分混合,调节pH在7.0~7.4;加水定容,随后利用氯化钠调节渗透压在280~350mOsm/kg;用0.22μm的滤膜过滤,获得悬浮培养BHK-21细胞的CD培养基。
3.一种如权利要求1至2任一项所述全悬浮培养BHK-21细胞的CD培养基在悬浮BHK-21细胞培养中使用125毫升摇瓶培养的培养工艺。
4.如权利要求3所述的工艺,其特征在于:包括低密与高密两种接种密度接种,其中低密的接种密度为3E5,高密的接种密度为10E5;选择经过不同代次传代的BHK21细胞,F10和F40,F10为复苏后经过10次传代的悬浮BHK21细胞,F40为复苏后经过40次传代的悬浮BHK21细胞,F40代后细胞趋于老化。
5.如权利要求3所述的工艺,其特征在于:包括5%CO2与8%CO2两种不同含量的二氧化碳浓度进行摇瓶培养测试BHK21细胞生长。
6.如权利要求3所述的工艺,其特征在于:包括32.5℃与36.5℃两种不同温度进行摇瓶培养测试BHK21细胞生长。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111190990.6A CN113817666A (zh) | 2021-10-13 | 2021-10-13 | 一种全悬浮培养bhk-21细胞的cd培养基及其摇瓶培养工艺 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111190990.6A CN113817666A (zh) | 2021-10-13 | 2021-10-13 | 一种全悬浮培养bhk-21细胞的cd培养基及其摇瓶培养工艺 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113817666A true CN113817666A (zh) | 2021-12-21 |
Family
ID=78920489
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111190990.6A Pending CN113817666A (zh) | 2021-10-13 | 2021-10-13 | 一种全悬浮培养bhk-21细胞的cd培养基及其摇瓶培养工艺 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113817666A (zh) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102268403A (zh) * | 2011-08-01 | 2011-12-07 | 上海米迪生物技术有限公司 | 适于幼仓鼠肾细胞大规模单细胞悬浮培养的无血清培养基 |
CN103555658A (zh) * | 2013-11-07 | 2014-02-05 | 令世鑫 | 一种bhk-21细胞全悬浮培养的无血清培养基 |
CN104395459A (zh) * | 2012-06-15 | 2015-03-04 | 默克专利有限公司 | 用于产生细胞培养基的方法 |
CN105018416A (zh) * | 2014-07-15 | 2015-11-04 | 内蒙古金源康生物工程有限公司 | 一种悬浮培养bhk-21细胞的无血清无动物源培养基及其配制方法 |
CN106032526A (zh) * | 2015-03-12 | 2016-10-19 | 北京天信和生物科技有限公司 | 一种动物细胞培养基及其制备方法和应用 |
CN106399224A (zh) * | 2016-12-13 | 2017-02-15 | 昆明润什生物科技有限公司 | 无血清无蛋白细胞培养基 |
CN106635953A (zh) * | 2016-12-13 | 2017-05-10 | 昆明润什生物科技有限公司 | 无血清无蛋白细胞培养基 |
CN110592000A (zh) * | 2019-08-13 | 2019-12-20 | 苏州易迈吉生物医药科技有限公司 | 一种支持bhk细胞高密度悬浮培养的无血清培养基 |
CN110799638A (zh) * | 2017-05-26 | 2020-02-14 | 耶拿弗里德里希·席勒大学 | 含有聚(噁唑啉)稳定剂的细胞培养物和聚(噁唑啉)用于稳定细胞培养物的用途 |
-
2021
- 2021-10-13 CN CN202111190990.6A patent/CN113817666A/zh active Pending
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102268403A (zh) * | 2011-08-01 | 2011-12-07 | 上海米迪生物技术有限公司 | 适于幼仓鼠肾细胞大规模单细胞悬浮培养的无血清培养基 |
CN104395459A (zh) * | 2012-06-15 | 2015-03-04 | 默克专利有限公司 | 用于产生细胞培养基的方法 |
CN103555658A (zh) * | 2013-11-07 | 2014-02-05 | 令世鑫 | 一种bhk-21细胞全悬浮培养的无血清培养基 |
CN105018416A (zh) * | 2014-07-15 | 2015-11-04 | 内蒙古金源康生物工程有限公司 | 一种悬浮培养bhk-21细胞的无血清无动物源培养基及其配制方法 |
CN106032526A (zh) * | 2015-03-12 | 2016-10-19 | 北京天信和生物科技有限公司 | 一种动物细胞培养基及其制备方法和应用 |
CN106399224A (zh) * | 2016-12-13 | 2017-02-15 | 昆明润什生物科技有限公司 | 无血清无蛋白细胞培养基 |
CN106635953A (zh) * | 2016-12-13 | 2017-05-10 | 昆明润什生物科技有限公司 | 无血清无蛋白细胞培养基 |
CN110799638A (zh) * | 2017-05-26 | 2020-02-14 | 耶拿弗里德里希·席勒大学 | 含有聚(噁唑啉)稳定剂的细胞培养物和聚(噁唑啉)用于稳定细胞培养物的用途 |
US20200339945A1 (en) * | 2017-05-26 | 2020-10-29 | Friedrich-Schiller-Universitaet Jena | Cell cultures comprising poly(oxazoline) stabilizers and use of poly(oxazolines) for stabilizing cell cultures |
CN110592000A (zh) * | 2019-08-13 | 2019-12-20 | 苏州易迈吉生物医药科技有限公司 | 一种支持bhk细胞高密度悬浮培养的无血清培养基 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109337861B (zh) | 一种支持产物高表达的cho细胞无血清培养基 | |
CN105018416B (zh) | 一种悬浮培养bhk-21细胞的无血清无动物源培养基及其配制方法 | |
CN107460159A (zh) | 无血清、无蛋白补料培养基及其制备方法和运用 | |
CN106635953B (zh) | 无血清无蛋白细胞培养基 | |
CN110343666B (zh) | 一种cho细胞培养的补料培养基及其制备方法和应用 | |
CN112795531B (zh) | 一种cho细胞无血清无蛋白培养基及其用途 | |
CN101760442A (zh) | 适于mdck细胞大规模贴壁培养和单细胞悬浮培养的无血清培养基 | |
CN111996161B (zh) | 一种cho细胞无血清无蛋白培养基及其用途 | |
CN102876626A (zh) | 支持cho高密度悬浮生长的无血清无蛋白全化学成分界定的培养基 | |
CN102268403A (zh) | 适于幼仓鼠肾细胞大规模单细胞悬浮培养的无血清培养基 | |
CN103555658A (zh) | 一种bhk-21细胞全悬浮培养的无血清培养基 | |
CN111019883B (zh) | Cho细胞悬浮培养的无血清无蛋白培养基及其用途 | |
CN106399224B (zh) | 无血清无蛋白细胞培养基 | |
CN105543163A (zh) | 一种用于全悬浮培养mdck细胞的无血清培养基 | |
CN101418330A (zh) | 适于nso细胞大规模培养及抗体生产的无蛋白培养基 | |
CN106190950A (zh) | 一种cho细胞无血清无蛋白培养基及其制备方法 | |
CN108359632A (zh) | Mdck细胞系、复制病毒的方法及其应用 | |
CN107841482A (zh) | Mdck细胞无血清悬浮培养技术生产h9亚型流感疫苗 | |
CN111944741A (zh) | Mdck细胞系的悬浮培养驯化方法 | |
CN101580864A (zh) | 一菌双酶生产光学纯l-丙氨酸的方法 | |
CN114107178B (zh) | 一种Vero细胞无血清基础培养基及其制备方法 | |
CN108103003B (zh) | 一种适应pk-15全悬浮生长的无血清培养基及其制备方法和应用于pk-15细胞的全悬浮驯化方法 | |
CN113817666A (zh) | 一种全悬浮培养bhk-21细胞的cd培养基及其摇瓶培养工艺 | |
CN113913368A (zh) | 适合cho细胞大规模悬浮扩增培养的无血清培养基及其制备和应用 | |
CN113943694B (zh) | 一种支持多种疫苗细胞贴壁或悬浮培养的通用型无血清培养基及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211221 |